| Description | Background: Bupropion SR ( Zyban) has been shown in randomized controlled trials to be an efficacious pharmacological aid for smoking cessation; however, recent reports have raised serious concerns about the breadth of its applicability without complications or contraindications. Methods: We examined this issue in a well-documented medical population, i.e. veterans volunteering to participate in a smoking cessation treatment research program involving the use of bupropion SR. Results: Overall, 22% of the 78 subjects who met the study criteria were appropriate for and completed the course of medication. Conclusions: Thus, bupropion SR in nicotine-dependent veterans may not be broadly applicable when conservative prescribing guidelines are carefully followed. Copyright (C) 2004 S. Karger AG, Basel. | |
University of Nevada, Reno
